TABLE 3.
Cancer screening outcome stratified by P/LP, VUS, and B/LB genetic test results
| Breast | P/LP (%) | VUS (%) | B/LB (%) |
|---|---|---|---|
| Conley 202017 (mammogram) | 90.0 | 90.0 | 94.8 |
| Garcia 201420 (mammogram) | 7.0 | 26.5 | NA |
| Conley 202017 (breast MRI) | 30.0 | 33.3 | 32.8 |
| Garcia 201420 (breast MRI) | 3.0 | 3.0 | NA |
| Hamilton 201921 (breast MRI) | 50.0 | 69.2 | NA |
| Hamilton 201921 (other) | 62.5 | 56.1 | NA |
| Ovarian | |||
| Conley 202017 (CA-125) | 25.0 | 7.1 | 11.0 |
| Garcia 201420 (CA-125) | 2.0 | 16.2 | NA |
| Conley 202017 (TVUS) | 56.2 | 38.1 | 26.8 |
| Garcia 201420 (TVUS) | 2.3 | 17.5 | NA |
| Colorectal | |||
| Chang 201916 (colonoscopy) | 4.5 | 8.9 | 9.8 |
Note: % refers to the proportion of participants who underwent screening.
Abbreviations: B/LB, benign or likely benign; CA-125: cancer antigen-125; P/LP, pathogenic or likely pathogenic; TVUS: transvaginal ultrasound; VUS: variant of uncertain significance.